Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development
Tóm tắt
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, inflammatory disorder that affects synovial joints, both small and large joints, in a symmetric pattern. This disorder usually does not directly cause death but significantly reduces the quality of life and life expectancy of patients if left untreated. There is no cure for RA but, patients are usually on long-term disease modifying anti-rheumatic drugs (DMARDs) to suppress the joint inflammation, to minimize joint damage, to preserve joint function, and to keep the disease in remission. RA is strongly associated with various immune cells and each of the cell type contributes differently to the disease pathogenesis. Several types of immunomodulatory molecules mainly cytokines secreted from immune cells mediate pathogenesis of RA, hence complicating the disease treatment and management. There are various treatments for RA depending on the severity of the disease and more importantly, the patient’s response towards the given drugs. Early diagnosis of RA and treatment with (DMARDs) are known to significantly improve the treatment outcome of patients. Sensitive biomarkers are crucial in early detection of disease as well as to monitor the disease activity and progress. This review aims to discuss the pathogenic role of various immune cells and immunological molecules in RA. This review also highlights the importance of understanding the immune cells in treating RA and in exploring novel biomarkers.
Từ khóa
Tài liệu tham khảo
(2018, February 15). Chronic Rheumatic Conditions. Available online: http://www.who.int/chp/topics/rheumatic/en/.
Ferri, F.F. (2018). Rheumatoid arthritis. Ferri’s Clinical Advisor, Elsevier. [20th ed.].
Kellerman, R.D., and Bope, E.T. (2018). Rheumatoid arthritis. Conn’s Current Therapy, Elsevier. [70th ed.].
Brassard, 2006, Antirheumatic drugs and the risk of tuberculosis, Clin. Inf. Dis., 43, 717, 10.1086/506935
Navarra, 2014, Risk of tuberculosis with anti-tumor necrosis factor-α therapy: Substantially higher number of patients at risk in Asia, Int. J. Rheum. Dis., 17, 291, 10.1111/1756-185X.12188
Mewar, 2011, Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors, Br. J. Pharmacol., 162, 785, 10.1111/j.1476-5381.2010.01099.x
Dixon, 2010, Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR), Ann. Rheum. Dis., 69, 522, 10.1136/ard.2009.118935
(2018, February 27). Rheumatoid Arthritis Treatment. Available online: http://www.hopkinsarthritis.org/arthritis-info/rheumatoid-arthritis/ra-treatment/.
Semerano, 2016, Developments with investigational Janus kinase inhibitors for rheumatoid arthritis, Expert Opin. Investig. Drugs, 25, 1355, 10.1080/13543784.2016.1249565
Monti, 2015, Rheumatoid arthritis treatment: The earlier the better to prevent joint damage, RMD Open, 1, e000057, 10.1136/rmdopen-2015-000057
Bugatti, 2014, B cells in rheumatoid arthritis: From pathogenic players to disease biomarkers, BioMed Res. Int., 2014, 681678, 10.1155/2014/681678
Giltiay, 2012, B-cell selection and the development of autoantibodies, Arthritis Res. Ther., 14, S1, 10.1186/ar3918
Browne, 2012, Regulation of B-cell responses by Toll-like receptors, Immunology, 136, 370, 10.1111/j.1365-2567.2012.03587.x
Samuels, 2005, Impaired early B cell tolerance in patients with rheumatoid arthritis, J. Exp. Med., 201, 1659, 10.1084/jem.20042321
Meffre, 2011, The establishment of early B cell tolerance in humans: Lessons from primary immunodeficiency diseases, Ann. N. Y. Acad. Sci., 1246, 1, 10.1111/j.1749-6632.2011.06347.x
Menard, 2011, Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis, Arthritis Rheum., 63, 1237, 10.1002/art.30164
Ehrenstein, 2004, Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy, J. Exp. Med., 200, 277, 10.1084/jem.20040165
Rapetti, 2015, B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis, Ann. Rheum. Dis., 74, 294, 10.1136/annrheumdis-2013-204049
Aarvak, 2011, Cell-cell interactions in synovitis: Antigen presenting cells and T cell interaction in rheumatoid arthritis, Arthritis Res., 3, 13, 10.1186/ar135
Schlegel, P.M., Steiert, I., Kötter, I., and Müller, C.A. (2013). B cell contribute to heterogeneity of IL-17 producing cells in rheumatoid arthritis and healthy controls. PLoS ONE, 8.
Nakagawa, 1998, RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis, Biochem. Biophys. Res. Commun., 253, 395, 10.1006/bbrc.1998.9788
Cope, 2007, The central role of T cells in rheumatoid arthritis, Clin. Exp. Rheumatol., 25, S4
Meednu, 2016, Production of RANKL by memory B cells: A link between B cells and bone erosion in rheumatoid arthritis, Arthritis Rheumatol., 68, 805, 10.1002/art.39489
Podojil, 2009, Molecular mechanisms of T cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy, Immunol. Rev., 229, 337, 10.1111/j.1600-065X.2009.00773.x
Williams, 2007, Effector and memory CTL differentiation, Annu. Rev. Immunol., 25, 171, 10.1146/annurev.immunol.25.022106.141548
Kalden, 2001, The balance of Th1/Th2 cytokines in rheumatoid arthritis, Best Pract. Res. Clin. Rheumatol., 15, 677, 10.1053/berh.2001.0187
Alunno, 2015, Altered immunoregulation in rheumatoid arthritis: The role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications, Mediat. Inflamm., 2015, 751793, 10.1155/2015/751793
Hussein, 2016, Th-17 cells and serum IL-17 in rheumatoid arthritis patients: Correlation with disease activity and severity, Egypt. Rheumatol., 38, 1, 10.1016/j.ejr.2015.01.001
Suurmond, 2011, Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium, Arthritis Res. Ther., 13, R150, 10.1186/ar3466
Gaffen, 2009, Role of IL-17 in the pathogenesis of rheumatoid arthritis, Curr. Rheumatol. Rep., 11, 365, 10.1007/s11926-009-0052-y
Ciccia, 2015, Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis, Rheumatology (Oxford), 54, 2264, 10.1093/rheumatology/kev252
Chowdhury, 2018, Synovial IL-9 facilitates neutrophil survival, function and differentiation of Th17 cells in rheumatoid arthritis, Arthritis Res. Ther., 20, 18, 10.1186/s13075-017-1505-8
Cooles, 2013, Treg cells in rheumatoid arthritis: An update, Curr. Rheumatol. Rep., 15, 352, 10.1007/s11926-013-0352-0
Boissier, 2009, Regulatory T cells (Treg) in rheumatoid arthritis, Jt. Bone Spine, 79, 10, 10.1016/j.jbspin.2008.08.002
Morita, T., Shima, Y., Wing, J.B., Sakaguchi, S., Ogata, A., and Kumanogoh, A. (2016). The proportion of regulatory T cells in patients with rheumatoid arthritis: A meta-analysis. PLoS ONE, 11.
Mamdouh, 2015, FoxP3+T regulatory cells in rheumatoid arthritis and the imbalance of the Treg/TH17 cytokine axis, Egypt. Rheumatol., 37, 7, 10.1016/j.ejr.2014.06.004
Rao, 2018, T cells that help B cells in chronically inflamed tissues, Front. Immunol., 9, 1924, 10.3389/fimmu.2018.01924
Rao, 2017, Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis, Nature, 542, 110, 10.1038/nature20810
Bondeson, 2006, The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis, Arthritis Res. Ther., 8, R187, 10.1186/ar2099
Davignon, 2013, Targeting monocytes/macrophages in the treatment of rheumatoid arthritis, Rheumatology (Oxford), 52, 590, 10.1093/rheumatology/kes304
Kim, 2010, Targeted delivery of siRNA to macrophages for anti-inflammatory treatment, Mol. Ther., 18, 993, 10.1038/mt.2010.27
Onuora, 2018, Experimental arthritis: Anti-TNF kills the macrophage response, Nat. Rev. Rheumatol., 14, 64
Pham, 2011, Nanotherapeutic approaches for the treatment of rheumatoid arthritis, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 3, 607, 10.1002/wnan.157
Rivellese, 2017, Mast cells in rheumatoid arthritis: Friends or foes?, Autoimmun. Rev., 16, 557, 10.1016/j.autrev.2017.04.001
Yu, 2017, The function of myeloid dendritic cells in rheumatoid arthritis, Rheumatol. Int., 37, 1043, 10.1007/s00296-017-3671-z
Khan, 2009, Dendritic cells as targets for therapy in rheumatoid arthritis, Nat. Rev. Rheumatol., 5, 566, 10.1038/nrrheum.2009.185
Hilkens, 2013, Tolerogenic dendritic cell therapy for rheumatoid arthritis: Where are we now?, Clin. Exp. Immunol., 172, 148, 10.1111/cei.12038
Shegarfi, 2012, Natural killer cells and their role in rheumatoid arthritis: Friend or foe?, Sci. World J., 2012, 491974, 10.1100/2012/491974
Feldmann, 1996, Role of cytokines in rheumatoid arthritis, Annu. Rev. Immunol., 14, 397, 10.1146/annurev.immunol.14.1.397
Brzustewicz, 2015, The role of cytokines in the pathogenesis of rheumatoid arthritis—Practical and potential application of cytokines as biomarkers and targets of personalized therapy, Cytokine, 76, 527, 10.1016/j.cyto.2015.08.260
Burska, 2014, Cytokines as Biomarkers in Rheumatoid Arthritis, Med. Inflamm., 2014, 545493, 10.1155/2014/545493
Alam, 2017, Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy, Biomed. Pharmacother., 92, 615, 10.1016/j.biopha.2017.05.055
Mateen, 2016, Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis, Clin. Chim. Acta, 455, 161, 10.1016/j.cca.2016.02.010
Choy, 2012, Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis, Rheumatology (Oxford), 51, v3, 10.1093/rheumatology/kes113
Griesmacher, 2001, Autoantibodies associated with rheumatic diseases, Clin. Chem. Lab. Med., 39, 189, 10.1515/CCLM.2001.031
Song, 2010, Autoantibodies in rheumatoid arthritis: Rheumatoid factors and anticitrullinated protein antibodies, QJM-Int. J. Med., 103, 139, 10.1093/qjmed/hcp165
Tseng, 2018, High levels of soluble GPR56/ADGRG1 are associated with positive rheumatoid factor and elevated tumor necrosis factor in patients with rheumatoid arthritis, J. Microbiol. Immunol. Infect., 51, 485, 10.1016/j.jmii.2016.11.010
Vossenaar, 2002, Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value, Arthritis Res., 4, 87, 10.1186/ar464
Vossenaar, 2004, Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis, Clin. Appl. Immunol. Rev., 4, 239, 10.1016/j.cair.2003.11.001
Sidorov, 2017, Fc fragments of immunoglobulin G are an inductor of regulatory rheumatoid factor and a promising therapeutic agent for rheumatic diseases, Int. J. Biol. Macromol., 95, 938, 10.1016/j.ijbiomac.2016.10.081
Aggarwal, 2009, Anti-citrullinated peptide antibody (ACPA) assays and their role in the diagnosis of rheumatoid arthritis, Arthritis Rheum., 61, 1472, 10.1002/art.24827
Manca, 2017, Anti-citrullinated peptide antibodies profiling in established rheumatoid arthritis, Jt. Bone Spine, 85, 441, 10.1016/j.jbspin.2017.07.009
Derksen, 2017, The role of autoantibodies in the pathophysiology of rheumatoid arthritis, Semin. Immunopathol., 39, 437, 10.1007/s00281-017-0627-z
Yee, 2015, Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis, Immunol. Res., 61, 24, 10.1007/s12026-014-8560-x
Kumar, 2017, Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease-modifying antirheumatic drugs, Reumatologia, 55, 4, 10.5114/reum.2017.66680
Shi, 2015, The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis, Arthritis Res. Ther., 17, 339, 10.1186/s13075-015-0860-6
Wang, 2015, Keratin 8 is a novel autoantigen of rheumatoid arthritis, Biochem. Biophys. Res. Commun., 465, 665, 10.1016/j.bbrc.2015.07.161
Vossenaar, 2004, Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin, Arthritis Res. Ther., 6, R142, 10.1186/ar1149
Fadda, 2016, Serum matrix metalloproteinase-3 in rheumatoid arthritis patients: Correlation with disease activity and joint destruction, Egypt. Rheumatol., 38, 153, 10.1016/j.ejr.2016.01.001
Niki, Y., Takeuchi, T., Nakayama, M., Nagasawa, H., Kurasawa, T., Yamada, H., Toyama, Y., and Miyamoto, T. (2012). Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy. PLoS ONE, 7.
Paleolog, 2009, The vasculature in rheumatoid arthritis: Cause or consequence?, Int. J. Exp. Pathol., 90, 249, 10.1111/j.1365-2613.2009.00640.x
Fardellone, 2014, Bone remodelling markers in rheumatoid arthritis, Mediat. Inflamm., 2014, 484280, 10.1155/2014/484280
Heo, 2014, Hyaluronan nanoparticles bearing γ-secretase inhibitor: In vivo therapeutic effects on rheumatoid arthritis, J. Control. Release, 192, 295, 10.1016/j.jconrel.2014.07.057
Paiva, 2017, Matrix metalloproteinases in bone resorption, remodelling, and repair, Prog. Mol. Biol. Transl. Sci., 148, 203, 10.1016/bs.pmbts.2017.05.001
Darweesh, 2010, Serum and synovial cartilage oligomeric matrix protein (COMP) in patients with rheumatoid arthritis and osteoarthritis, Ind. J. Rheumatol., 5, 112, 10.1016/S0973-3698(10)60556-0
Lorenzo, 2017, Quantification of cartilage oligomeric matrix protein (COMP) and a COMP neoepitope in synovial fluid of patients with different joint disorders by novel automated assays, Osteoarthr. Cartil., 25, 1436, 10.1016/j.joca.2017.04.004
Choy, 2003, Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis, Ann. Rheum. Dis., 62, ii68, 10.1136/ard.62.suppl_2.ii68
Shaw, 2003, B cell therapy for rheumatoid arthritis: The rituximab (anti-CD20) experience, Ann. Rheum. Dis., 62, ii55, 10.1136/ard.62.suppl_2.ii55
Taylor, 2003, Anti-cytokines and cytokines in the treatment of rheumatoid arthritis, Curr. Pharm. Des., 9, 1095, 10.2174/1381612033454991
Albrecht, 2010, Side effects and management of side effects of methotrexate in rheumatoid arthritis, Clin. Exp. Rheumatol., 28, S95
Guo, 2018, Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies, Bone Res., 6, 15, 10.1038/s41413-018-0016-9
Perdriger, 2009, Infliximab in the treatment of rheumatoid arthritis, Biologics, 3, 183
Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial, Arthritis Rheum., 48, 35, 10.1002/art.10697
Haraoui, 2007, Etanercept in the treatment of rheumatoid arthritis, Ther. Clin. Risk Manag., 3, 99, 10.2147/tcrm.2007.3.1.99
Mease, 2011, Certolizumab pegol in the treatment of rheumatoid arthritis: A comprehensive review of its clinical efficacy and safety, Rheumatology (Oxford), 50, 261, 10.1093/rheumatology/keq285
Singh, 2010, Golimumab for rheumatoid arthritis: A systematic review, J. Rheumatol., 37, 1096, 10.3899/jrheum.091466
Mok, 2014, Rituximab for the treatment of rheumatoid arthritis: An update, Drug Des. Dev. Ther., 8, 87
Kaneko, 2013, Tocilizumab in rheumatoid arthritis: Efficacy, safety and its place in therapy, Ther. Adv. Chronic Dis., 4, 15, 10.1177/2040622312466908
Boyce, 2018, Sarilumab: Review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis, Ann. Pharmacother., 52, 780, 10.1177/1060028018761599
Ni, 2013, Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: Tofacitinib, ISRN Rheumatol., 2013, 357904, 10.1155/2013/357904
Gras, 2016, Baricitinib: JAK inhibition for rheumatoid arthritis, Drugs Today, 52, 543, 10.1358/dot.2016.52.10.2525742
Langdon, 2018, Regulatory T-cell dynamics with abatacept treatment in rheumatoid arthritis, Int. Rev. Immunol., 37, 206, 10.1080/08830185.2018.1465943
(2018, August 01). Australian New Zealand Clinical Trials Registry Trial Review. Available online: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373425.
(2018, August 03). NIH US National Library of Medicine Clinical Trials.gov, Available online: https://clinicaltrials.gov/ct2/show/NCT03410056.
Crotti, 2017, Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: Evidence to date, Drug Des. Dev. Ther., 11, 211, 10.2147/DDDT.S104233
Schiff, 2015, Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: Results of a randomised, double-blind, placebo-controlled, phase 3 study, RMD Open, 1, e000037, 10.1136/rmdopen-2014-000037
Huizinga, 2017, Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis, Arthritis Res. Ther., 19, 53, 10.1186/s13075-017-1267-3
Cook, 2018, Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: Focus on mavrilimumab, Ther. Adv. Musculoskelet. Dis., 10, 29, 10.1177/1759720X17752036
Kivitz, 2016, FRI0209 MORAb-022, an anti-granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody (MAB): Results of the first study in patients with mild-to-moderate rheumatoid arthritis (RA), Ann. Rheum. Dis., 75, 507, 10.1136/annrheumdis-2016-eular.3186
Molfino, 2016, Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma, BMJ Open, 6, e007709, 10.1136/bmjopen-2015-007709
Smolen, 2015, Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: Results from a phase III multicentre, randomised, double-blind study, Ann. Rheum. Dis., 74, 1567, 10.1136/annrheumdis-2014-207090
Mahtani, 2013, Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: Primary care diagnostic technology update, Br. J. Gen. Pract., 63, 553, 10.3399/bjgp13X673919
(2018, September 19). Lilly Press Release Archives. Available online: http://lilly.mediaroom.com/index.php?s=9042&item=136985.
Luime, 2010, Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review, Ann. Rheum. Dis., 69, 337, 10.1136/ard.2008.103283
Maksymowych, 2014, Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis, J. Rheumatol., 41, 2104, 10.3899/jrheum.131446
Anderson, 2012, Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice, Arthritis Care Res. (Hoboken), 64, 640, 10.1002/acr.21649
(2018, September 19). Study of KB003 in Biologics-Inadequate Rheumatoid Arthritis, Available online: https://clinicaltrials.gov/ct2/results?term=NCT00995449.
Centola, M., Cavet, G., Shen, Y., Ramanujan, S., Knowlton, N., Swan, K.A., Turner, M., Sutton, C., Smith, D.R., and Haney, D.J. (2013). Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS ONE, 8.
Hambardzumyan, 2017, A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure, Arthritis Rheumatol., 69, 953, 10.1002/art.40019
Curtis, 2017, Reanalysis of the multi-biomarker disease activity score for assessing disease activity in the AMPLEstudy: Comment on the article by Fleischmann et al, Arthritis Rheumatol., 69, 863, 10.1002/art.39981
2011, Predictors of response to biologic therapies in rheumatoid arthritis, Rheumatol. Clin., 7, 141
Lv, Q., Yin, Y., Li, X., Shan, G., Wu, X., Liang, D., Li, Y., and Zhang, X. (2014). The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: A meta-analysis. PLoS ONE, 9.
Fabris, 2010, Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab, Autoimmun. Highlights, 1, 87, 10.1007/s13317-010-0013-5
Marotta, 2014, SAT0070 levels of 14-3-3Eta predict good EULAR response to anti-TNF treatment in patients with rheumatoid arthritis, Ann. Rheum. Dis., 73, 615, 10.1136/annrheumdis-2014-eular.3426
Morozzi, 2007, Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis, Clin. Rheumatol., 26, 1335, 10.1007/s10067-006-0520-y
Choi, 2015, MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, Ann. Rheum. Dis., 74, 499, 10.1136/annrheumdis-2013-203923
Isgren, 2012, High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis, Semin. Arthritis Rheum., 41, 652, 10.1016/j.semarthrit.2011.08.005
Benham, 2015, Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients, Sci. Transl. Med., 7, 290ra87, 10.1126/scitranslmed.aaa9301
Shabahang, 2010, Recent patents on immunoregulatory DNA vaccines for autoimmune diseases and allograft rejection, Recent Pat. DNA Gene Seq., 4, 122, 10.2174/187221510793205700
Ratsimandresy, 2011, Active immunization against IL-23p19 improves experimental arthritis, Vaccine, 29, 9329, 10.1016/j.vaccine.2011.09.134
Cohen, 2008, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, Arthritis Rheum., 58, 1299, 10.1002/art.23417
Takeuchi, 2016, Effect of denosumab on Japanese patients with rheumatoid arthritis: A dose-response study of AMG 162 (Denosumab) in patients with rheumatoid arthritis on methotrexate to validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial, Ann. Rheum. Dis., 75, 983, 10.1136/annrheumdis-2015-208052
Feng, 2014, Therapeutic effects of PADRE-BAFF autovaccine on rat adjuvant arthritis, BioMed Res. Int., 2014, 854954, 10.1155/2014/854954
Mould, 2008, Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model, Rheumatology (Oxford), 47, 263, 10.1093/rheumatology/kem369
Rosenthal, 2015, Rheumatoid arthritis vaccine therapies: Perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis, Expert Rev. Vaccines, 14, 891, 10.1586/14760584.2015.1026330
Chiu, 2017, Denosumab: Targeting the RANKL pathway to treat rheumatoid arthritis, Expert Opin Biol. Ther., 17, 119, 10.1080/14712598.2017.1263614
Malemud, 2015, Vaccine development for rheumatoid arthritis, Glob. Vaccines Immunol., 1, 2, 10.15761/GVI.1000102
Nandakumar, 2005, Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis, J. Immunol. Methods, 304, 126, 10.1016/j.jim.2005.06.017
Hasselberg, 2009, Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis, Arthritis Rheum., 60, 1672, 10.1002/art.24566
Zimmerman, 2010, CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model, Int. Immunopharmacol., 10, 412, 10.1016/j.intimp.2009.12.016
Dzhambazov, 2006, Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules, J. Immunol., 176, 1525, 10.4049/jimmunol.176.3.1525
Kochetkova, 2008, Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells, J. Immunol., 181, 2741, 10.4049/jimmunol.181.4.2741